Morganroth J, Pearlman A S, Dunkman W B, Horowitz L N, Josephson M E, Michelson E L
Am Heart J. 1979 Nov;98(5):621-8. doi: 10.1016/0002-8703(79)90288-6.
Ethmozin, a phenothiazine derivative, was developed in the Soviet Union as a new antiarrhythmic agent. We evaluated ethmozin using a controlled single-blinded in-hospital protocol in 14 ambulatory patients with ventricular ectopy ranging from an average of 48 to 1,801 depolarizations per hour and in eight patients with atrial ectopy ranging from 63 to 693 depolarizations per hour. Placebo was administered for the first 3 days, followed by ethmozin from 2.4 to 11.2 mg./Kg./day administered orally every 8 hours for 7 days and concluding with placebo for the final 3 days. Continuous 24-hour long-term electrocardiographic monitoring for 13 days was employed to measure drug efficacy accurately. Six of eight (75 per cent) patients with atrial ectopy and 10 of 14 (71 per cent) patients with ventricular ectopy had statistically significant reductions in ectopy during ethmozin therapy. Atrial ectopy was reduced at a lower dose and plasma level of ethmozin than was ventricular ectopy. With the exception of mild nausea in one patient, no side effects of ethmozin therapy were noted. Ethmozin appears to be a well-tolerated, effective antiarrhythmic agent with a dosage regimen that can promote patient compliance for long-term use.
乙吗噻嗪是一种吩噻嗪衍生物，在苏联作为一种新型抗心律失常药物被研发出来。我们采用一项对照单盲住院方案对乙吗噻嗪进行了评估，研究对象为14例门诊室性早搏患者，其室性早搏平均每小时48次至1801次去极化，以及8例房性早搏患者，其房性早搏每小时63次至693次去极化。前3天给予安慰剂，随后7天每8小时口服乙吗噻嗪，剂量为2.4至11.2毫克/千克/天，最后3天再次给予安慰剂。采用连续24小时的长期心电图监测13天，以准确测量药物疗效。8例房性早搏患者中有6例（75%），14例室性早搏患者中有10例（71%）在乙吗噻嗪治疗期间早搏次数有统计学意义的减少。房性早搏在乙吗噻嗪剂量和血药浓度较低时就有所减少，而室性早搏则不然。除1例患者出现轻度恶心外，未观察到乙吗噻嗪治疗的其他副作用。乙吗噻嗪似乎是一种耐受性良好、有效的抗心律失常药物，其给药方案可提高患者长期使用的依从性。
